China Pharma Holdings, Inc. (CPHI)
Market Cap | 3.75M |
Revenue (ttm) | 5.54M |
Net Income (ttm) | -4.74M |
Shares Out | 19.25M |
EPS (ttm) | -0.35 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 159,510 |
Open | 0.190 |
Previous Close | 0.200 |
Day's Range | 0.187 - 0.200 |
52-Week Range | 0.170 - 0.700 |
Beta | 0.66 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 13, 2024 |
About CPHI
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain;... [Read more]
Full Company ProfileFinancial Performance
In 2023, China Pharma Holdings's revenue was $7.01 million, a decrease of -13.48% compared to the previous year's $8.10 million. Losses were -$3.08 million, -22.50% less than in 2022.
Financial StatementsNews
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
HAIKOU, China , Aug. 19, 2024 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
HAIKOU, China , Feb. 23, 2024 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on ...
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
HAIKOU, China , Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialt...
China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs
HAIKOU, China , Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its who...
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
HAIKOU, China , Feb. 24, 2023 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on...
China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask
HAIKOU, China , Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19
HAIKOU, China , Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Announced the Acquisition of Dry Eye Disease Therapeutic Device Project
HAIKOU, China , Dec. 5, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spec...
China Pharma Announces Receipt of Noncompliance Notice from NYSE American
HAIKOU, China , Dec. 2, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Dece...
China Pharma Announces Receipt of Notification of NYSE American Listing Deficiency
HAIKOU, China , Oct. 1, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI; the "Company") today announced that on September 26, 2022, the Company received notification (the "Defici...
China Pharma Announced the Submission of a Plan of Compliance to NYSE American
HAIKOU, China , July 18, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on Jul...
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
HAIKOU, China, March 31, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
HAIKOU, China, Nov. 12, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
HAIKOU, China, Aug. 13, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated spe...
China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval
HAIKOU, China , Aug. 5, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its Can...
China Pharma to Launch Highly Purified NMN+PQQ Product
HAIKOU, China, June 9, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced plans to laun...
China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue
HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial res...
China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port
HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy sta...
China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results
HAIKOU CITY, China , March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integra...
China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript
China Pharma Holdings Inc. (CPHI) CEO Zhilin Li on Q4 2019 Results - Earnings Call Transcript
China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript
China Pharma's (CPHI) CEO Zhilin Li on Q2 2019 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q1 2019 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript
China Pharma Holdings, Inc. (CPHI) CEO Zhilin Li on Q4 2018 Results - Earnings Call Transcript